PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-100.00%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-83.05%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
7.21%
Positive EBIT growth while GNPX is negative. John Neff might see a substantial edge in operational management.
7.21%
Positive operating income growth while GNPX is negative. John Neff might view this as a competitive edge in operations.
7.01%
Positive net income growth while GNPX is negative. John Neff might see a big relative performance advantage.
8.82%
EPS growth 1.25-1.5x GNPX's 7.52%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
8.82%
Diluted EPS growth 1.25-1.5x GNPX's 7.52%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
0.91%
Share reduction more than 1.5x GNPX's 8.81%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.91%
Diluted share reduction more than 1.5x GNPX's 8.80%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
1.55%
Positive OCF growth while GNPX is negative. John Neff would see this as a clear operational advantage vs. the competitor.
1.40%
Positive FCF growth while GNPX is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while GNPX stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
91.07%
Positive long-term OCF/share growth while GNPX is negative. John Neff would see a structural advantage in sustained cash generation.
81.18%
5Y OCF/share CAGR above 1.5x GNPX's 23.62%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
13.88%
3Y OCF/share CAGR under 50% of GNPX's 31.82%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
98.43%
Net income/share CAGR above 1.5x GNPX's 41.84% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
78.58%
5Y net income/share CAGR above 1.5x GNPX's 34.55%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
-7.39%
Negative 3Y CAGR while GNPX is 35.31%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
109.82%
Positive growth while GNPX is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
14.99%
Positive 5Y equity/share CAGR while GNPX is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-59.15%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
8.48%
Asset growth well under 50% of GNPX's 17.75%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
19.47%
BV/share growth above 1.5x GNPX's 8.51%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-6.20%
We’re deleveraging while GNPX stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-18.94%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
28.45%
SG&A growth well above GNPX's 19.79%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.